MR-Guided Microwave Ablation in T1 Renal Cell Carcinoma: Initial Results in Clinical Routine

<div>Kaplan–Meier progression-free survival (PFS) with MR-guided treatment. The 1-, 2-, and 3-year PFS rates were 96.9%, 93.8%, and 83.9%, respectively. Mean PFS rate was 33.972 months (95% CI: 33.045, 35.900) .</div>

BioMed Research International

fig3

Figure 3

Figure 3: MR-Guided Microwave Ablation in T1 Renal Cell Carcinoma: Initial Results in Clinical Routine 